Nijmegen

• A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants with Pulmonary Hypertension … Ended recruitment
  2024-513991-16-00 4 2025-01-17 Pulmonary Hypertension Associated with Interstitial Lung Disease
• A Phase 3 Global Study to Evaluate AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 Ended recruitment
  2024-511378-60-00 5 2024-12-11 Myotonic Dystrophy Type 1
• A trial to learn how safe AZD7798 is and how well it works in adults with ileal Crohn’s disease who have an ileostomy Ended recruitment
  2024-514407-33-00 4 2024-12-10 Crohn’s Disease and an Ileostomy
• An open-label study to collect safety and effectiveness information on long-term treatment with vamorolone in boys with Duchenne Muscular Dy … Ended recruitment
  2024-512828-12-00 6 2024-12-05 Duchenne Muscular Dystrophy
• A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended recruitment
  2023-510487-12-00 4 2024-11-29 Crohn's Disease
• Trial Examining Methods for Antidepressant Discontinuation (TEMPO) Ended recruitment
  2024-511997-66-00 6 2024-11-22 Major Depressive Disorder
• A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended recruitment
  2024-516511-24-00 11 2024-11-14 Chronic myeloid leukaemia
• GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failu … Ended recruitment
  2024-510581-17-00 4 2024-11-05 Adult subjects with New York Heart Association (NYHA) Class III conges
• Effect of different drugs on the immune response during inflammation: the DEDICATE-LPS study Ended recruitment
  2023-506556-24-00 4 2024-10-24 Inflammatory response following human endotoxemia in healthy volunteer
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• A phase 4, randomised vaccination study in healthy adults to investigate the effects of acellular pertussis vaccine on colonisation with Bor … Ended recruitment
  2023-508416-35-00 6 2024-10-16 Pertussis or 'whooping cough'
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended recruitment
  2023-509716-29-00 9 2024-09-23 Solid Tumors, Colorectal Cancer and Breast Cancer
• AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous … Ended recruitment
  2024-511195-33-00 3 2024-09-23 Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
• Safe Stop ipi-nivo Ended recruitment
  2024-516938-34-00 5 2024-09-11 Melanoma
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended recruitment
  2023-504922-20-00 5 2024-08-23 Hypercholesterolemia
• MAD Ended recruitment
  2024-516379-34-00 6 2024-08-02 Myopia
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• DUTCH-WAIST Ended recruitment
  2022-501392-81-00 6 2024-07-25 Obesity
• [18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary origin Ended recruitment
  2023-505592-69-00 5 2024-07-12 Carcinoma of Unknown Primary
• Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Ended recruitment
  2023-509047-26-00 1 2024-06-13 Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease

Showing 337–360 of 568 trials